Caladrius Biosciences (NASDAQ:CLBS – Get Rating) and Marpai (NASDAQ:MRAI – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.
Institutional and Insider Ownership
17.1% of Caladrius Biosciences shares are owned by institutional investors. Comparatively, 47.4% of Marpai shares are owned by institutional investors. 2.2% of Caladrius Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Caladrius Biosciences and Marpai’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Caladrius Biosciences||N/A||N/A||-$27.47 million||($0.52)||-1.21|
|Marpai||$14.23 million||2.11||-$15.98 million||N/A||N/A|
Marpai has higher revenue and earnings than Caladrius Biosciences.
This table compares Caladrius Biosciences and Marpai’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for Caladrius Biosciences and Marpai, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Caladrius Biosciences presently has a consensus price target of $6.00, suggesting a potential upside of 852.38%. Given Caladrius Biosciences’ higher possible upside, analysts plainly believe Caladrius Biosciences is more favorable than Marpai.
Marpai beats Caladrius Biosciences on 5 of the 8 factors compared between the two stocks.
Caladrius Biosciences Company Profile (Get Rating)
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Marpai Company Profile (Get Rating)
Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market. It also offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. The company was incorporated in 2021 and is based in Tampa, Florida.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.